Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells

• Jessica E. C. Jones,

  Affiliation Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research Unit, Pfizer Inc, Cambridge, Massachusetts, United States of America

  ⨯
• William P. Esler ,

  * E-mail: Cecile.Vernochet@pfizer.com (CV); William.Esler@pfizer.com (WPE)

  Affiliation Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research Unit, Pfizer Inc, Cambridge, Massachusetts, United States of America

  ⨯
• Rushi Patel,

  Affiliation Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research Unit, Pfizer Inc, Cambridge, Massachusetts, United States of America

  ⨯
• Adhiraj Lanba,

  Affiliation Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research Unit, Pfizer Inc, Cambridge, Massachusetts, United States of America

  ⨯
• Nicholas B. Vera,

  Affiliation Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research Unit, Pfizer Inc, Cambridge, Massachusetts, United States of America

  ⨯
• Jeffrey A. Pfefferkorn,

  Affiliation Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research Unit, Pfizer Inc, Cambridge, Massachusetts, United States of America

  ⨯
• Cecile Vernochet

  * E-mail: Cecile.Vernochet@pfizer.com (CV); William.Esler@pfizer.com (WPE)

  Affiliation Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research Unit, Pfizer Inc, Cambridge, Massachusetts, United States of America

  ⨯